CY1110027T1 - Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων - Google Patents
Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειωνInfo
- Publication number
- CY1110027T1 CY1110027T1 CY20101100416T CY101100416T CY1110027T1 CY 1110027 T1 CY1110027 T1 CY 1110027T1 CY 20101100416 T CY20101100416 T CY 20101100416T CY 101100416 T CY101100416 T CY 101100416T CY 1110027 T1 CY1110027 T1 CY 1110027T1
- Authority
- CY
- Cyprus
- Prior art keywords
- combination
- pyrimidylaminobenzamide
- prevention
- treatment
- neoplastic diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 150000004926 Imatinib derivatives Chemical class 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68775805P | 2005-06-03 | 2005-06-03 | |
| EP06760628A EP1893213B1 (en) | 2005-06-03 | 2006-06-02 | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110027T1 true CY1110027T1 (el) | 2015-01-14 |
Family
ID=36968749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100416T CY1110027T1 (el) | 2005-06-03 | 2010-05-13 | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7767688B2 (enExample) |
| EP (1) | EP1893213B1 (enExample) |
| JP (2) | JP5281887B2 (enExample) |
| KR (1) | KR101276425B1 (enExample) |
| CN (1) | CN101180060B (enExample) |
| AT (1) | ATE457727T1 (enExample) |
| AU (1) | AU2006255559B2 (enExample) |
| BR (1) | BRPI0611506A2 (enExample) |
| CA (1) | CA2608814C (enExample) |
| CY (1) | CY1110027T1 (enExample) |
| DE (1) | DE602006012313D1 (enExample) |
| DK (1) | DK1893213T3 (enExample) |
| ES (1) | ES2339593T3 (enExample) |
| HR (1) | HRP20100265T1 (enExample) |
| IL (1) | IL187408A0 (enExample) |
| MA (1) | MA29565B1 (enExample) |
| MX (1) | MX2007015159A (enExample) |
| NO (1) | NO20080037L (enExample) |
| NZ (1) | NZ563446A (enExample) |
| PL (1) | PL1893213T3 (enExample) |
| PT (1) | PT1893213E (enExample) |
| RU (1) | RU2430727C2 (enExample) |
| SI (1) | SI1893213T1 (enExample) |
| TN (1) | TNSN07453A1 (enExample) |
| WO (1) | WO2006132930A1 (enExample) |
| ZA (1) | ZA200709473B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101276425B1 (ko) * | 2005-06-03 | 2013-06-19 | 노파르티스 아게 | 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 |
| TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
| EP2382976A1 (en) | 2010-04-30 | 2011-11-02 | Hiroshima University | Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer |
| CN102719530B (zh) * | 2012-05-07 | 2013-11-06 | 厦门艾德生物医药科技有限公司 | 一种用于检测PDGFRα基因突变的引物、探针及试剂盒 |
| KR101386697B1 (ko) * | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| RU2020108342A (ru) | 2017-07-26 | 2021-08-26 | Эф Тэ Эф Фарма Привейт Лимитед | Жидкие дозируемые лекарственные формы иматиниба |
| EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
| KR101276425B1 (ko) * | 2005-06-03 | 2013-06-19 | 노파르티스 아게 | 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 |
-
2006
- 2006-06-02 KR KR1020077028059A patent/KR101276425B1/ko not_active Expired - Fee Related
- 2006-06-02 CA CA2608814A patent/CA2608814C/en not_active Expired - Fee Related
- 2006-06-02 RU RU2007147957/15A patent/RU2430727C2/ru not_active IP Right Cessation
- 2006-06-02 AT AT06760628T patent/ATE457727T1/de active
- 2006-06-02 EP EP06760628A patent/EP1893213B1/en active Active
- 2006-06-02 BR BRPI0611506-3A patent/BRPI0611506A2/pt not_active IP Right Cessation
- 2006-06-02 DE DE602006012313T patent/DE602006012313D1/de active Active
- 2006-06-02 US US11/915,650 patent/US7767688B2/en not_active Expired - Fee Related
- 2006-06-02 PL PL06760628T patent/PL1893213T3/pl unknown
- 2006-06-02 SI SI200630626T patent/SI1893213T1/sl unknown
- 2006-06-02 NZ NZ563446A patent/NZ563446A/en not_active IP Right Cessation
- 2006-06-02 WO PCT/US2006/021307 patent/WO2006132930A1/en not_active Ceased
- 2006-06-02 ES ES06760628T patent/ES2339593T3/es active Active
- 2006-06-02 PT PT06760628T patent/PT1893213E/pt unknown
- 2006-06-02 DK DK06760628.5T patent/DK1893213T3/da active
- 2006-06-02 JP JP2008514865A patent/JP5281887B2/ja not_active Expired - Fee Related
- 2006-06-02 MX MX2007015159A patent/MX2007015159A/es active IP Right Grant
- 2006-06-02 CN CN2006800181195A patent/CN101180060B/zh not_active Expired - Fee Related
- 2006-06-02 AU AU2006255559A patent/AU2006255559B2/en not_active Ceased
- 2006-06-02 HR HR20100265T patent/HRP20100265T1/hr unknown
-
2007
- 2007-11-02 ZA ZA200709473A patent/ZA200709473B/xx unknown
- 2007-11-15 IL IL187408A patent/IL187408A0/en not_active IP Right Cessation
- 2007-11-30 TN TNP2007000453A patent/TNSN07453A1/en unknown
- 2007-12-26 MA MA30509A patent/MA29565B1/fr unknown
-
2008
- 2008-01-03 NO NO20080037A patent/NO20080037L/no not_active Application Discontinuation
-
2010
- 2010-04-02 US US12/753,184 patent/US8653093B2/en not_active Expired - Fee Related
- 2010-05-13 CY CY20101100416T patent/CY1110027T1/el unknown
-
2012
- 2012-09-14 JP JP2012203258A patent/JP2013035853A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2014028I1 (el) | Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης | |
| EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| LT2878297T (lt) | Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai | |
| CY1119601T1 (el) | Προαγωγεις αποπτωσης | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| NL1026203A1 (nl) | Verbindingen toepasbaar voor de behandeling van ziekten. | |
| ATE412414T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen | |
| BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| ATE458487T1 (de) | Tumorbehandlung mit gliotoxin-derivaten | |
| EP2574340A3 (en) | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor | |
| WO2007010013A3 (en) | Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases | |
| WO2007010012A3 (en) | Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor | |
| WO2007047950A3 (en) | Use of sumoylation inhibitors for the treatment of neurodegenerative disease | |
| TH2001005610A (th) | สารประกอบเฮเทอโรไซคลิกที่เป็นสารปรับภูมิคุ้มกัน |